-
Expert Insights: Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms – A Focus on Myelofibrosis_Srdan Verstovsek, MD, PhD_Naveen Pemmaraju, MD
23:21
-
Therapeutic Options for Patients with JAK-Inhibitor–Naïve Myelofibrosis_Naveen Pemmaraju, MD
21:38
-
Treatment Selection and Emerging Therapeutic Options in JAK-Inhibitor Refractory/ Intolerant Myelofibrosis_Srdan Verstovsek, MD, PhD
16:54
-
Panel Discussion and Audience Q&A
6:53
-
Risk-Stratification and Management Strategies for MPNs_Elizabeth Hexner, MD, MSTR
18:01
-
Later Phase Trials for MPNs, CML and Systemic Mastocytosis_Mark Heaney, MD, PhD; #hemeupdates2022
16:20
-
New treatments for MPNs, CML, and systemic mastocytosis_Ellen Ritchie, MD; #BeyondTheCongress
17:44
-
Updates in the management of MDS_Michael Savona, MD; #BeyondTheCongress
16:32
-
Podium to Practice: Recent Updates on the Treatment of Myeloproliferative Neoplasms – Highlights from the 2021 Hematology Annual Meeting_John Mascarenhas, MD_Alessandro Vannucchi, MD
30:03
-
Naveen Pemmaraju, MD; The University of Texas MD Anderson Cancer Center; 5Live #ASH21
7:42
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Anand Tandra, MD; Franciscan Health Cancer Center; 5Live #ASH21
3:03
Key insights from the 2021 Annual Hematology meeting in Atlanta
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company